Neurol. pro Praxi, 2006; 6: 310-312

Trombolytická terapie akutního mozkového infarktu

MUDr. David Goldemund, MUDr. Robert Mikulík
I. neurologická klinika LF MU a FN u sv. Anny Brno

Hlavním cílem trombolytické te­rapie (TL) je dosáhnout rekanalizace mozkové tepny uzavřené trombem nebo embolem. Standardní terapií akutního mozkového infarktu se stala intravenózní trombolýza v časovém okně do tří hodin. Zaváděny jsou nové postupy, jejichž cílem je zvýšit procento rekanalizací a prodloužit terapeutické okno. Přehled těchto metod a dosavadní výsledky proběhlých studií jsou náplní tohoto textu.

Keywords: akutní mozkový infarkt, trombolýza

Published: February 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Goldemund D, Mikulík R. Trombolytická terapie akutního mozkového infarktu. Neurol. praxi. 2006;7(6):310-312.
Download citation

References

  1. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35 (4): 904-911. Go to PubMed...
  2. Furlan AJ et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37 (5): 1227-1231. Go to original source... Go to PubMed...
  3. Furlan A et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. Jama 1999; 282 (21): 2003-2011. Go to original source... Go to PubMed...
  4. Hacke W et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363 (9411): 768-774. Go to original source... Go to PubMed...
  5. Hacke W et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352 (9136): 1245-1251. Go to original source... Go to PubMed...
  6. Hacke W et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36 (1): 66-73. Go to original source... Go to PubMed...
  7. Hacke W et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 1999; 53 (Suppl 4): 3-14. Go to PubMed...
  8. Qureshi AI et al. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 2001; 49 (1): 41-48; discussion 48-50. Go to original source... Go to PubMed...
  9. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333 (24): 1581-1587.




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.